Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID
{{output}}
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting plasma cell... ...